111732
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肝移植受者中成功应用舒巴坦-德拉巴坦治疗产 OXA-23 型鲍曼不动杆菌肺炎
Authors Yin G, Liu Z, Fu Z, Zhong Z, Ye S, Pan H
Received 22 June 2025
Accepted for publication 9 October 2025
Published 17 October 2025 Volume 2025:18 Pages 5343—5349
DOI https://doi.org/10.2147/IDR.S548066
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sandip Patil
Guangjiao Yin,1,2 Zhongzhong Liu,1,2 Zhen Fu,1,2 Zibiao Zhong,1,2 Shaojun Ye,1,2 Huaqin Pan1– 3
1Department of Organ Transplantation, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Wuhan, 430071, People’s Republic of China; 2Department of Transplant Intensive Care Unit, Zhongnan Hospital of Wuhan University, Transplant Center of Wuhan University, Wuhan, 430071, People’s Republic of China; 3Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People’s Republic of China
Correspondence: Shaojun Ye, Department of Organ Transplantation, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, 169 Eastlake Road, Wuhan, Hubei, 430071, People’s Republic of China, Email 86987100@qq.com Huaqin Pan, Department of Transplant Intensive Care Unit, Zhongnan Hospital of Wuhan University, Transplant Center of Wuhan University, 169 Eastlake Road, Wuhan, Hubei, 430071, People’s Republic of China, Email phq2012@whu.edu.cn
Abstract: Liver transplant recipients face a higher risk of multidrug-resistant (MDR) infections because of preoperative comorbidities, extensive antibiotic use, immunosuppressive therapy, and prolonged mechanical ventilation. Carbapenem-resistant Acinetobacter baumannii (CRAB) remains one of the most challenging pathogens in this group. We report a case of a liver transplant recipient with OXA-23-producing Acinetobacter baumannii pneumonia. Initial treatment with polymyxin B and eravacycline produced unsatisfactory results and worsened renal dysfunction during treatment. Later, administration of sulbactam-durlobactam (SUL-DUR) combined with meropenem resulted in significant clinical improvement. Follow-up CT scans showed notable resolution, and the patient successfully recovered, with renal function restored and eventual discharge. This case highlights the difficulty of managing OXA-23-producing Acinetobacter baumannii in liver transplant patients, especially those with kidney impairment. SUL-DUR showed effective therapy with a much lower risk of nephrotoxicity compared to previously used agents.
Keywords: liver transplantation, carbapenem-resistant Acinetobacter baumannii, sulbactam-durlobactam, multidrug-resistant infection
1Department of Organ Transplantation, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Wuhan, 430071, People’s Republic of China; 2Department of Transplant Intensive Care Unit, Zhongnan Hospital of Wuhan University, Transplant Center of Wuhan University, Wuhan, 430071, People’s Republic of China; 3Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People’s Republic of China
Correspondence: Shaojun Ye, Department of Organ Transplantation, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, 169 Eastlake Road, Wuhan, Hubei, 430071, People’s Republic of China, Email 86987100@qq.com Huaqin Pan, Department of Transplant Intensive Care Unit, Zhongnan Hospital of Wuhan University, Transplant Center of Wuhan University, 169 Eastlake Road, Wuhan, Hubei, 430071, People’s Republic of China, Email phq2012@whu.edu.cn
Abstract: Liver transplant recipients face a higher risk of multidrug-resistant (MDR) infections because of preoperative comorbidities, extensive antibiotic use, immunosuppressive therapy, and prolonged mechanical ventilation. Carbapenem-resistant Acinetobacter baumannii (CRAB) remains one of the most challenging pathogens in this group. We report a case of a liver transplant recipient with OXA-23-producing Acinetobacter baumannii pneumonia. Initial treatment with polymyxin B and eravacycline produced unsatisfactory results and worsened renal dysfunction during treatment. Later, administration of sulbactam-durlobactam (SUL-DUR) combined with meropenem resulted in significant clinical improvement. Follow-up CT scans showed notable resolution, and the patient successfully recovered, with renal function restored and eventual discharge. This case highlights the difficulty of managing OXA-23-producing Acinetobacter baumannii in liver transplant patients, especially those with kidney impairment. SUL-DUR showed effective therapy with a much lower risk of nephrotoxicity compared to previously used agents.
Keywords: liver transplantation, carbapenem-resistant Acinetobacter baumannii, sulbactam-durlobactam, multidrug-resistant infection